Telik Announces Initiation of Two Phase 2 Randomized TELINT...( PALO ALTO Calif. May 20 /- Telik ...),Health

PALO ALTO, Calif., May 20 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK), today announced it has initiated two Phase 2 TELINTRA(R) studies -- one with TELINTRA tablets in myelodysplastic syndrome, or MDS, and a second with TELINTRA tablets in cancer patients at risk for chemotherapy-induced neutropenia, or CIN.

As previously reported, Telik completed a successful 65 patient Phase 2 study with the IV formulation of TELINTRA in MDS, and a dose-escalating Phase 1 study of the oral formulation of TELINTRA tablets in 45 patients. The data from the multicenter Phase 1 study was presented at the December 2007 meeting of the American Society of Hematology and the positive results support the initiation of these new Phase 2 clinical trials.

The randomized Phase 2 study with TELINTRA tablets in MDS is expected to enroll 86 patients, with an anticipated 20 sites participating in the study. Two dose schedules of TELINTRA tablets will be evaluated in low-to-intermediate one risk MDS patients. The primary objective of the study is to determine the hematologic improvement rate in erythroid or red blood cell precursors in each treatment group as assessed by the International Working Group criteria.

One group of patients will be given a starting dose of 4500mg of TELINTRA daily in divided doses for two weeks followed by one week off therapy. The second group of patients will receive the same dose of TELINTRA for three weeks followed by one week off therapy. Patients will receive treatment for up to six months, and if patients are continuing to receive clinical benefit after this initial period, the treatment may be extended for an additional six months with continuous daily dosing.

The second randomized Phase 2 study with
'/>"/>